Abstract:Background: Bmi1, a polycomb-group protein, maintains stem cell self-renewal and is frequently overexpressed in cancers. Upregulation of Bmi1 by Twist1 can promote tumor-initiating capability and Epithelial-mesenchymal transition (EMT) by repressing E-cadherin expression. It has been demonstrated that Post-EMT breast cancer cells express cancer stem cell (CSC) markers including Bmi1, but display decreased ERα expression. ERα is a ligand-activated nuclear hormone receptor that regulates the transcription of E2-responsive genes in diverse target cells. It9s reported that ligand-activated ERα could repress slug transcription by binding to the half-site ERE element in its promoter, and then regulate E-cadherin and EMT. Herein, we hypothesized that ERα signaling might regulate E-cadherin and EMT through Bmi1. Methods: First, we determined Bmi1 and ERα expression at both mRNA and protein levels by quantitative RT-PCR and Western blot in various breast cancer cell lines. Further, we quantitatively analyzed mRNA and protein levels of Bmi1 as well as its down-stream genes including E-cadherin after silencing ERα in T47D cells with siRNA, or after overexpressing ERα in BT549 cells. The chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) were also performed to investigate whether ERα binds directly to Bmi1 promoter region. Luciferase assay with Bmi1 reporter was performed to ERα mediated regulation. To identify whether ERα regulates EMT, transwell and matrigel invasion, flow cytometry, mammosphere assay and wound healing assay were performed to invasion, metastases and characterize stem-cell properties of EMT. Finally, we analyzed the expression of ERα, Bmi1 and E-cadherin in human breast cancer specimens with immunohistochemistry. Results: The study showed that Bmi1 inversely correlated with ERα expression in different subtypes of breast cancer cells. We further confirmed that Bmi1 was upregulated at both mRNA and protein levels and E-cadherin was downregulated with siRNA against ERα in T47D cells, and Bmi1 was downregulated and E-cadherin was upregulated when overexpressing ERα in BT549 cells with qRT-PCR and western blot analyses. The present study also demonstrated that ERα could directly binds to the half-ERE region of the Bmi1 gene and repressing Bmi1 expression transcriptionally with CHIP/EMSA and reporter analyses. Overexpression of ERα in BT549 cell significantly decreased levels of migration of transwell and wounding healing, invasiveness, CD44 high /CD24 low population, and the capabilities of mammosphere formation. Conclusions: Our results demonstrated that ERα can suppress EMT through transcriptionally down-regulating Bmi-1 and its down-stream genes in human breast cancer cells. The inverse relationship between ERα and Bmi1 expression further supports the epithelial phenotype of ERα positive tumors or mesenchymal phenotype of ERα negative tumors. Our findings provide a novel mechanistic insight into how ERα regulates EMT, and is of valuable for developing biomarkers to predict prognosis and targeted therapies in breast cancers in the future. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-07-11.

ZMIZ1 enhances ERα-dependent expression of E2F2 in breast cancer

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

KRAB-containing Zinc Finger Protein ZNF496 Inhibits Breast Cancer Cell Proliferation by Selectively Repressing ERα Activity.

Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells.

Zinc Finger Protein 593 Promotes Breast Cancer Development by Ensuring DNA Damage Repair and Cell Cycle Progression

ZMIZ2 promotes the development of triple-receptor negative breast cancer

Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression

EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis

Abstract P1-07-11: ERa regulates epithelial-mesenchymal transition in breast cancers through suppressing Bmi1 expression

Oncogenic Functions of the EMT-related Transcription Factor ZEB1 in Breast Cancer

Knockdown of ZBTB7A Inhibits Cell Proliferation of Breast Cancer Through Regulating the Ubiquitination of Estrogen Receptor Alpha.

EZH2 Participates in Malignant Biological Behavior of Epithelial Ovarian Cancer Through Regulating the Expression of BRCA1

High-Throughput Cell-Based Screening Reveals A Role for Znf131 As A Repressor of Eralpha Signaling

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A

Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer

ER is an RNA-binding protein sustaining tumor cell survival and drug resistance

ZRANB1 is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer

ZNF623 contributes to breast carcinoma progress by recruiting CtBP1 to regulate NF-κB pathway

The Zeb1-Cxcl1 Axis Impairs the Antitumor Immune Response by Inducing M2 Macrophage Polarization in Breast Cancer